| Name | Title | Contact Details |
|---|
Parallax was founded in January 1999 to make control equity investments in lower middle market software and related technology companies. Parallax invests in companies with revenues between $5 and $100 million where there are creative opportunities to significantly enhance a company`s value. We welcome complex transactions or turnarounds including leveraged buy-outs, recapitalizations, corporate divestitures, spin-offs and build-ups. By seeking companies that are undergoing significant change or transition, Parallax distinguishes itself from other buyers who are unable or unwilling to provide a hands-on-approach as many of these opportunities so often require. We actively pursue investments in the USA, Canada, “Developed” Europe and Asia-Pacific. Since 1999, Parallax has participated in over 25 transactions representing over $250 million in transaction value worldwide. Our previous and current portfolio companies generate over $1 billion of annual revenues and have provided significant returns for our investors, partners and employees. Parallax has built an exceptional track record of transitioning divisions, subsidiaries and product lines into successful stand-alone entities or integrating them into current portfolio companies. Unique from other financial buyers, Parallax will take an active management role in its portfolio companies – assuming a number of interim positions within a company as required. Additionally, Parallax is further supported by an in-house staff of M&A professionals, accountants, HR specialists, and technical personnel. By leveraging this unique blend of financial capabilities and operational execution, Parallax is able to solve the array of issues associated with the sale and transition of a business.
Omega Funds is a leading international investment firm that creates and invests in life sciences companies that target the world`s most urgent medical needs. Ω is the last letter of the Greek alphabet. Our investment process starts by focusing on the end goal – delivering impactful medicines to patients. We aim to invest in exceptional founders and entrepreneurs and impactful products and platforms across multiple therapeutic areas, including oncology, immunology, rare diseases, precision medicine and others. Early seed or late stage public financing. Large markets or rare diseases. Established targets or novel technologies. We are guided by our conviction in people, products and breakthrough ideas, not by conventional categories. Our investments span a variety of instruments from early venture rounds, to late-stage investing, direct secondary transactions, as well as company founding and creation. Omega Funds has raised more than $1 billion since its inception in 2004 and is headquartered in Boston, Massachusetts, USA.
TOMS Capital is a family office run by Noam Gottesman, and handles his personal investments, art, and philanthopy
Red Hook Management is a Morristown, NJ-based company in the Financial Services sector.
Cogent Partners is a Dallas, TX-based company in the Financial Services sector.